R & D

Anacor Pipeline

Topical Anti-Inflammatories

Atopic Dermatitis
Next generation PDE-4 inhibitor
Cytokine Suppression Program

Systemic Antibiotics


Animal Health

Phase 1
Phase 2
Phase 3

Lilly licensed this compound from us in December 2012 for the potential treatment of an animal health indication and is responsible for all further development and commercialization. We are eligible to receive additional development and regulatory milestones, as well as tiered royalties from the high single digits to in-the-tens on any future sales.

Lilly® is a registered trademark of Eli Lilly and Company.